Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Accumulated Expenses (2017 - 2025)

Entera Bio has reported Accumulated Expenses over the past 8 years, most recently at $1.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 74.49% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2025, up 74.49%, and an annual FY2025 reading of $1.5 million, up 74.49% over the prior year.
  • Accumulated Expenses came in at $1.5 million for Q4 2025, up from $1.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $2.8 million in Q4 2021 to a low of $651000.0 in Q3 2022.
  • Median Accumulated Expenses over the past 5 years was $1.3 million (2025), compared with a mean of $1.3 million.
  • The sharpest move saw Accumulated Expenses surged 110.6% in 2021, then tumbled 55.98% in 2022.
  • Over 5 years, Accumulated Expenses stood at $2.8 million in 2021, then tumbled by 55.98% to $1.2 million in 2022, then fell by 29.12% to $874000.0 in 2023, then changed by 0.0% to $874000.0 in 2024, then surged by 74.49% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Accumulated Expenses are $1.5 million (Q4 2025), $1.2 million (Q3 2025), and $1.3 million (Q2 2025).